Xpreza
Brand Name: Xpreza
Composition: Azacitidine for Injection (100 mg / vial)
Manufacturer: Natco Pharma Ltd.
Product Description
Medical Info
Xpreza is a prescription-only oncology medication containing Azacitidine (100 mg) in a vial for injection. Classified as a hypomethylating agent, it functions by interfering with the growth of cancer cells and is primarily used to treat adults with specific subtypes of myelodysplastic syndromes (MDS), including refractory anemia, and certain forms of acute myeloid leukemia (AML). The drug is intended for administration under strict oncological supervision. Proper reconstitution and handling are critical, and patients must be closely monitored for potential side effects. The formulation is suitable only for subcutaneous or intravenous use, as indicated.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
